Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01772173 · ClinicalTrials.gov registry record
Retinal Vessel Measurements as Clinically Useful Predictors in Veterans
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 800
- Enrollment target
NCT01772173: Completed study, sponsored by VA Office of Research and Development.
NCT01772173 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 800 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01772173 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 800 participants
- Enrollment target
Study Summary
Diabetic complications are an important source of blindness and mortality among Veterans. Their occurrence is unpredictable because of the highly variable effect of factors such as weight, diet and exercise. Improved prediction of diabetes complications has the potential to improve the care for Veterans with diabetes, especially if this can be done without any extra effort for the Veterans or their caretakers. All Veterans with diabetes in VHA are required to undergo annual retinal photography to screen for current diabetic retinopathy. The investigators have recently developed an automated, precise, fast, novel tool for measuring retinal vessels in these images. Manual measurement of retinal vessels has shown that these can predict future -not current- development of hypertension and also diabetic retinopathy. If the investigators can confirm that their tool can flag those Veterans at increased risk for developing these diabetes complications, this will allow earlier intervention and prevention. Because the tool only uses the images that are being taken anyway, there is no extra effort for either the Veteran or VA staff.
Interventions
- OTHER Vessel measurements
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2017-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01772173
The ClinicalTrials.gov registry entry for NCT01772173 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vessel measurements is the first listed.
NCT01772173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01772173 about?
NCT01772173 is a clinical study titled "Retinal Vessel Measurements as Clinically Useful Predictors in Veterans". Diabetic complications are an important source of blindness and mortality among Veterans. Their occurrence is unpredictable because of the highly variable effect of factors such as weight, diet and exercise. Improved prediction of diabetes complications has the potential to improve the care for Vete...
What is the current status of trial NCT01772173?
This trial is currently completed. The enrollment target is 800 participants. The study started on 2013-02-01. Estimated completion is 2017-03-01.
What interventions are being tested in trial NCT01772173?
The interventions under investigation include: Vessel measurements (OTHER).
Who is sponsoring clinical trial NCT01772173?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.